2. Academic Validation
  3. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists

5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists

  • Bioorg Med Chem Lett. 2003 May 19;13(10):1801-4. doi: 10.1016/s0960-894x(03)00257-9.
Hiroo Koyama 1,  Julia K Boueres,  Wei Han,  Edward J Metzger,  Jeffrey P Bergman,  Dominick F Gratale,  Daniel J Miller,  Richard L Tolman,  Karen L MacNaul,  Joel P Berger,  Thomas W Doebber,  Kwan Leung,  David E Moller,  James V Heck,  Soumya P Sahoo
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA. [email protected]
PMID: 12729668 DOI: 10.1016/s0960-894x(03)00257-9
Abstract

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR Agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

Figures